PriceTargets.com logo

Fennec Pharmaceuticals - FRX Stock Price Target and Predictions

  • Consensus Rating: Strong Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 1 Strong Buy Ratings
C$12.69 As of 06/15/2026 05:20 PM ET
▲ +0.29 (2.34%)

This chart shows the closing price for FRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Fennec Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FRX

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Fennec Pharmaceuticals in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$12.69.

This chart shows the closing price for FRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Buy

The current consensus among 1 polled investment analysts is to buy (strong buy) stock in Fennec Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/22/2024
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2025
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/16/2026
  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/15/2026

Latest Recommendations

  • 1 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/11/2026B. Riley FinancialUpgradeStrong-Buy
11/18/2024StephensUpgradeStrong-Buy
11/22/2022Cantor FitzgeraldUpgradeNeutral ➝ Overweight
10/20/2022HC WainwrightReiterated RatingBuy
9/7/2022Capital One FinancialReiterated RatingOverweight
5/12/2022WedbushReiterated RatingOutperform
3/24/2022Maxim GroupReiterated RatingBuyC$10.00
11/30/2021Maxim GroupInitiated CoverageBuyC$10.00
11/30/2021Cantor FitzgeraldDowngradeOverweight ➝ Neutral
(Data available from 6/16/2021 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/17/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/16/2026
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/15/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/17/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/16/2026
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/16/2026
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/15/2026

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Fennec Pharmaceuticals logo
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand. PEDMARQSI is now commercially available in the U.K. and Germany. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection.
Read More

Today's Range

Now: C$12.69
Low: C$12.69
High: C$12.69

50 Day Range

MA: C$10.94
Low: C$8.10
High: C$13.88

52 Week Range

Now: C$12.69
Low: C$7.59
High: C$14.24

Volume

1,943 shs

Average Volume

1,286 shs

Market Capitalization

C$440.81 million

P/E Ratio

N/A

Dividend Yield

2.02%

Beta

3.518081

Frequently Asked Questions

What sell-side analysts currently cover shares of Fennec Pharmaceuticals?

The following Wall Street sell-side analysts have issued research reports on Fennec Pharmaceuticals in the last twelve months: B. Riley Financial, Inc..
View the latest analyst ratings for FRX.

What is the current price target for Fennec Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Fennec Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Fennec Pharmaceuticals in the next year.
View the latest price targets for FRX.

What is the current consensus analyst rating for Fennec Pharmaceuticals?

Fennec Pharmaceuticals currently has 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Strong Buy."
View the latest ratings for FRX.

What other companies compete with Fennec Pharmaceuticals?

Other companies that are similar to Fennec Pharmaceuticals include Cara Operations, Cronos Group, Tilray Brands, International Tower Hill Mines and Tervita. Learn More about companies similar to Fennec Pharmaceuticals.

How do I contact Fennec Pharmaceuticals' investor relations team?

Fennec Pharmaceuticals' physical mailing address is 68 Tw Alexander Dr PO Box 13628, DURHAM, NC 27709-3628, United States. The biopharmaceutical company's listed phone number is +1-919-6364530. The official website for Fennec Pharmaceuticals is fennecpharma.com. Learn More about contacing Fennec Pharmaceuticals investor relations.